CN101522683B - 可用作蛋白激酶抑制剂的吡唑并(1,5-a)(1,3,5)三嗪和吡唑并(1,5-a)嘧啶衍生物 - Google Patents

可用作蛋白激酶抑制剂的吡唑并(1,5-a)(1,3,5)三嗪和吡唑并(1,5-a)嘧啶衍生物 Download PDF

Info

Publication number
CN101522683B
CN101522683B CN2007800342168A CN200780034216A CN101522683B CN 101522683 B CN101522683 B CN 101522683B CN 2007800342168 A CN2007800342168 A CN 2007800342168A CN 200780034216 A CN200780034216 A CN 200780034216A CN 101522683 B CN101522683 B CN 101522683B
Authority
CN
China
Prior art keywords
amino
phenyl
pyrazolo
diaza
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800342168A
Other languages
English (en)
Chinese (zh)
Other versions
CN101522683A (zh
Inventor
储少嵩
聂喆
C·L·佩雷塔
P·E·埃里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaceutical (chengdu) Co Ltd
Original Assignee
Polaris Group Taiwan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polaris Group Taiwan filed Critical Polaris Group Taiwan
Publication of CN101522683A publication Critical patent/CN101522683A/zh
Application granted granted Critical
Publication of CN101522683B publication Critical patent/CN101522683B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800342168A 2006-09-18 2007-09-18 可用作蛋白激酶抑制剂的吡唑并(1,5-a)(1,3,5)三嗪和吡唑并(1,5-a)嘧啶衍生物 Active CN101522683B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84531406P 2006-09-18 2006-09-18
US60/845,314 2006-09-18
US11/856,476 US7517882B2 (en) 2006-09-18 2007-09-17 Protein kinase inhibitors
US11/856,476 2007-09-17
PCT/US2007/020231 WO2008036277A1 (en) 2006-09-18 2007-09-18 Pyraz0l0(l,5-a) (1, 3, 5) triazine and pyrazolo (1, 5-a) pyrimidine derivatives useful as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101522683A CN101522683A (zh) 2009-09-02
CN101522683B true CN101522683B (zh) 2013-02-27

Family

ID=39052753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800342168A Active CN101522683B (zh) 2006-09-18 2007-09-18 可用作蛋白激酶抑制剂的吡唑并(1,5-a)(1,3,5)三嗪和吡唑并(1,5-a)嘧啶衍生物

Country Status (11)

Country Link
US (2) US7517882B2 (enExample)
EP (1) EP2064214B1 (enExample)
JP (1) JP5232786B2 (enExample)
KR (1) KR101418619B1 (enExample)
CN (1) CN101522683B (enExample)
AU (1) AU2007297675B2 (enExample)
BR (1) BRPI0718459A2 (enExample)
CA (1) CA2663791C (enExample)
ES (1) ES2400450T3 (enExample)
TW (1) TWI472530B (enExample)
WO (1) WO2008036277A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
CN102056925A (zh) * 2008-04-07 2011-05-11 Irm责任有限公司 作为激酶抑制剂的化合物和组合物
EA025881B1 (ru) * 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
CN105209040A (zh) * 2013-03-15 2015-12-30 昂科迪塞恩股份有限公司 大环的盐可诱导的激酶抑制剂
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
ES2899196T3 (es) 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
JP2019527230A (ja) * 2016-07-28 2019-09-26 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 大環状キナーゼ阻害剤
AU2019364336B2 (en) 2018-10-22 2023-11-16 Alumis Inc. TYK2 inhibitors and uses thereof
AU2020239026B2 (en) * 2019-03-11 2025-10-09 Alumis Inc. TYK2 inhibitors and uses thereof
JP7595582B2 (ja) * 2019-03-26 2024-12-06 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826343A (zh) * 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并－喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10255343B4 (de) 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
RU2389731C2 (ru) 2004-06-02 2010-05-20 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1826343A (zh) * 2003-05-22 2006-08-30 法玛西雅意大利公司 吡唑并－喹唑啉衍生物、它们的制备方法和它们作为激酶抑制剂的用途

Also Published As

Publication number Publication date
JP5232786B2 (ja) 2013-07-10
CN101522683A (zh) 2009-09-02
AU2007297675A1 (en) 2008-03-27
ES2400450T3 (es) 2013-04-10
US20080070893A1 (en) 2008-03-20
CA2663791C (en) 2015-11-03
TW200837065A (en) 2008-09-16
KR20090083889A (ko) 2009-08-04
TWI472530B (zh) 2015-02-11
US7517882B2 (en) 2009-04-14
JP2010503690A (ja) 2010-02-04
AU2007297675B2 (en) 2012-09-20
US20090247501A1 (en) 2009-10-01
CA2663791A1 (en) 2008-03-27
EP2064214A1 (en) 2009-06-03
BRPI0718459A2 (pt) 2013-12-03
WO2008036277A1 (en) 2008-03-27
KR101418619B1 (ko) 2014-07-14
EP2064214B1 (en) 2013-01-30
HK1135688A1 (en) 2010-06-11

Similar Documents

Publication Publication Date Title
CN101522683B (zh) 可用作蛋白激酶抑制剂的吡唑并(1,5-a)(1,3,5)三嗪和吡唑并(1,5-a)嘧啶衍生物
AU2007316417B2 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
CN101801973B (zh) 6-三唑并哒嗪硫基苯并噻唑和苯并咪唑衍生物、其制备方法和作为药物和药物组合物的应用和作为met抑制剂的用途
EP2440559B1 (en) Egfr inhibitors and methods of treating disorders
EP3783000B1 (en) Macrocyclic kinase inhibitor
KR20180041757A (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
US20110263594A1 (en) Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors
EP3141552A1 (en) Thienopyrimidine derivatives having inhibitory activity for protein kinase
EP1477489A1 (en) Pyrrolopyrimidine derivatives
CN109721600A (zh) 一类含氮稠环化合物及其制备方法和用途
EP2615096B1 (en) Quinoxaline compound
WO2017206962A1 (zh) Flt3激酶的新型抑制剂及其用途
CN117645598A (zh) 氮杂二并多元稠环化合物及其药物组合物和应用
KR20180083426A (ko) 비스-피리다진 화합물 및 암 치료에서 이의 용도
HK1135688B (en) Pyrazolo (1,5-a)(1,3,5) triazine and pyrazolo (1,5-a) pyrimidine derivatives useful as protein kinase inhibitors
CN101321762A (zh) 三环内酰胺衍生物、它们的制备和作为药剂的应用
HK1069583A (en) Pyrrolopyrimidine derivatives

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135688

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135688

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160909

Address after: 611731 No. 198 Tian Sheng Road, hi tech Zone, Sichuan, Chengdu

Patentee after: Pharmaceutical (Chengdu) Co., Ltd.

Address before: Taipei City, Taiwan, China

Patentee before: Polaris Group